{"entity":{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","aka":[],"tldr":"A handful of ageing research reactors make most cancer isotopes. Coordinating their maintenance and funding reserve capacity would prevent the shortages that stop treatments.","summary":"Lutetium-177, iodine-131 and molybdenum-99 depend on a few research reactors (HFR Petten, BR2, MARIA, SAFARI-1, OPAL, several in Russia and the US), most over 50 years old. The OECD Nuclear Energy Agency's High-Level Group on Medical Radioisotopes coordinated molybdenum-99 after the 2009-10 crisis. The proposal is to extend that model formally to therapeutic isotopes: shared outage scheduling, an agreed reserve capacity margin funded by a per-dose levy, and public co-financing of the next generation of producers (PALLAS in the Netherlands, accelerator-based SHINE, new irradiation positions in existing reactors).","asOf":"2026-09-08","links":[{"label":"OECD NEA medical radioisotopes","url":"https://www.oecd-nea.org/jcms/pl_26262/medical-radioisotopes"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Coordinated scheduling and reserve capacity reduce clinic-reported therapeutic isotope shortage weeks by at least 80% and keep lutetium-177 spot prices stable during planned reactor outages.","rationale":"The molybdenum-99 experience showed that coordination, not new physics, ended a supply crisis; therapeutic isotopes now face the same concentration of supply with faster-growing demand.","test":"Publish a shared outage calendar and reserve-margin target for lutetium-177 producers within a year; track clinic-reported dose cancellations and prices against the prior three years.","maturity":"early-clinical","actor":"policy","cost":"large","horizonYears":5},"route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","neighbours":{"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}]}}